- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
Views: 46 Author: Unibest Industrial Publish Time: 2025-01-13 Origin: Site
Report generated for the week of 2025-01-13 by Unibest Digital Center. Current analysis scope only include the US FDA.
This week, there are 6 drugs in the patent and exclusivity list. They are:
- BAUSCH AND LOMB INC's BEPREVE, containing active ingredient BEPOTASTINE BESILATE
- ITALFARMACO SPA's DUVYZAT, containing active ingredient GIVINOSTAT HYDROCHLORIDE
- NOVARTIS PHARMACEUTICALS CORP's ENTRESTO & ENTRESTO SPRINKLE, containing active ingredient SACUBITRIL; VALSARTAN
- GLENMARK SPECIALTY SA's RYALTRIS, containing active ingredient MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE
- ABBVIE INC's RINVOQ, containing active ingredient UPADACITINIB
From BAUSCH AND LOMB INC; for treating itchiness associated with allergic conjunctivitis.
Approved in Sep 8, 2009, used as Reference Listed Drug and Reference Standard
There are no future patents for this application.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date | Patent Title |
|---|---|---|---|---|
| 8784789 | 2025-01-13 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
From ITALFARMACO SPA; for treating Duchenne Muscular Dystrophy.
Approved in Mar 21, 2024, used as Reference Listed Drug and Reference Standard
There are 3 future patent(s) for this application. The earliest expires on 2032-02-03, and the latest expires on 2036-10-28.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date | Patent Title |
|---|---|---|---|---|
| 7329689 | 2025-01-15 | Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester |
From NOVARTIS PHARMACEUTICALS CORP; for treating adults with chronic heart failure to help reduce the risk of death and hospitalization, and for treating certain children aged 1 year and older who have symptomatic heart failure.
Approved in Apr 12, 2024, used as Reference Listed Drug and Reference Standard
Approved in Apr 12, 2024, used as Reference Listed Drug
There are 3 future patent(s) for this application. The earliest expires on 2026-11-08, and the latest expires on 2037-02-02.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date | Patent Title |
|---|---|---|---|---|
| 8101659 | 2025-01-15 | Methods of treatment and pharmaceutical composition |
From NOVARTIS PHARMACEUTICALS CORP; for treating adults with chronic heart failure to help reduce the risk of death and hospitalization and to treat certain children aged 1 year and older who have symptomatic heart failure.
Approved in Jul 7, 2015, used as Reference Listed Drug
Approved in Jul 7, 2015, used as Reference Listed Drug
Approved in Jul 7, 2015, used as Reference Listed Drug and Reference Standard
There are 9 future patent(s) for this application. The earliest expires on 2025-07-15, and the latest expires on 2036-05-09.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date | Patent Title |
|---|---|---|---|---|
| 8101659 | 2025-01-15 | Methods of treatment and pharmaceutical composition |
From GLENMARK SPECIALTY SA; for treating symptoms of seasonal allergies in people 12 years of age and older.
Approved in Jan 13, 2022, used as Reference Listed Drug and Reference Standard
There are no future exclusivities for this application.
| Exclusivity Date | Exclusivity Use Definition |
|---|---|
| 2025-01-13 | NEW PRODUCT |
From ABBVIE INC; for treating several conditions that have inflammation as a characteristic symptom.
Approved in Aug 16, 2019, used as Reference Listed Drug
There are 6 future exclusivity(ies) for this drug product. The earliest expires on 2025-03-16, and the latest expires on 2031-04-26.
| Exclusivity Date | Exclusivity Use Definition |
|---|---|
| 2025-01-14 | TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, INCLUDING BIOLOGICS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE |
Approved in Jan 14, 2022, used as Reference Listed Drug
There are 6 future exclusivity(ies) for this drug product. The earliest expires on 2025-03-16, and the latest expires on 2031-04-26.
| Exclusivity Date | Exclusivity Use Definition |
|---|---|
| 2025-01-14 | TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, INCLUDING BIOLOGICS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE |
